Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-11-06
Target enrollment:
Participant gender:
Summary
Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based
paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer,
especially for squamous cell cancer. This study is conducted to evaluate the efficacy and
safety of nab-paclitaxel, carboplatin and concurrent radiotherapy in patients with local
advanced inoperable squamous cell lung cancer.